MOBILE AGENDA

San Diego, 30 November 2017 - 1 December 2017

Schedule

Create your personal agenda –check the favourite icon

Nov 3008:40
Conference pass

Status of US vaccine and immunotherapy research in 2017 and beyond

Keynotes
  • Drivers moving the immunotherapy sector forward and its potential
  • Hurdles in vaccines research and the consequence of antivaxxers in national immunity
  • What regulatory or policy changes could affect the science, technology and funding to this sector?
Nov 3009:20
Conference pass

Human Vaccine Project: How much of the immune response do we understand? Deciphering the human immunome for a better vaccine design

Keynotes
  • How have technological advances in next-generation DNA sequencing offered ways to probe the human immune system?
  • Results so far on the Human Immunome that could lead to acceleration of vaccine development
  • Working toward a complete catalogue of expressed human immune receptors
  • Challenges in interpreting the vast amount of data into meaningful information
Nov 3009:45
Conference pass

What can we learn from vaccine development for infectious diseases that can be applied to cancer and vice versa?

Keynotes
  • Bridging infectious disease vaccines with cancer immunotherapy
  • Technologies that are applicable to both including RNA vaccines
  • How to stimulate both humoral and cell-mediated immunity that are likely paramount for successful cancer immunotherapeutics
  • Understanding infectious vaccine approaches and immunological responses to strengthen cancer immunotherapeutic strategies
Nov 3010:25
Conference pass

NEW: Speed networking – Break the ice with your peers!

Keynotes
Allowing conference delegates to meet each other for a short space of time and exchange business cards. A unique feature guaranteeing heightened networking for all participants
Nov 3011:40
Conference pass

Chair’s opening remarks

Funding and Partnerships
Nov 3011:40
Conference pass
Nov 3011:40
Conference pass
Nov 3011:45
Conference pass

The Human Vaccine Project’s first clinical trial: Understanding the rules of lifelong immunological protection

Infectious Diseases
  • The importance of looking at all aspects of immune response and integrating this data to get an accurate reflection of response to vaccination
  • What distinguishes the 30% of people who have a good response after a single dose of Hep B vaccine
  • Results from initial study assessing immune responses of 10 healthy adults (ages 40-80) to a licensed hepatitis B vaccine, expansion into larger numbers and demographics
  • Outlook for 2018 and beyond:  projects looking at HPV vaccination – challenges to overcome
Nov 3011:45
Conference pass

Personalized cancer vaccines that target patients-specific mutations: Platforms amenable for neoantigen vaccination

Immunotherapy
  • Strategies for target antigen identification and validation 
  • Personalized vaccines-specific considerations in adjuvant selection
  • Challenges in clinical studies, i.e., patient selection, dose selection, efficacy determination and regulatory paths
Nov 3011:45
Conference pass

VC Panel: Choosing the correct investment. Funding opportunities and investment strategies

Funding and Partnerships
  • What VC firms look for in entrepreneurs and companies when making investments
  • At what stage do we invest?
  • Funding innovation and next-generation technology whilst existing under a financial microscope
Nov 3012:15
Conference pass

Lymph node fine needle aspirates to reveal correlates for immunization-induced neutralizing antibodies

Infectious Diseases
  • The central role of the germinal center response in generating neutralizing antibodies after HIV Env trimer immunization.
  • The importance of immunization route.
  • Lymph node fine needle aspirates can be used to analyze germinal centers in humans after immunization.
Nov 3012:15
Conference pass

The identification of tumor-host interactions that propagate an anti-tumor immune response

Immunotherapy
  • A deeper understanding of tumor-host interaction is essential for the development of effective immunotherapies
  • Designing successful clinical trials to identify responders and non-responders
  • Using the insight gained from clinical trials to identify which patients will benefit from which drug combinations
Nov 3012:30
Conference pass

Investment Banking Panel: Status of the US vaccine & immunotherapy market

Funding and Partnerships
  • Health of the US vaccine and immunotherapy market
  • What’s needed to offer private financing or public offerings
  • What do investors currently have an appetite for?
Nov 3012:45
Conference pass

Early innate immune responses to Hep B vaccination using single cell RNA sequencing approaches

Infectious Diseases
  • Using single cell transcriptomic analysis to more accurately define and evaluate vaccine responses, with Hep B as an example
  • What’s happening immediately after vaccination in the primary response?
  • Unique data challenges in integrating meaningful analysis into better vaccine design
  • Application of machine learning methods – can we predict how our immune system responds?
Nov 3012:45
Conference pass

Insights into combination studies across various tumour types

Immunotherapy
  • The rational for pursuing combination therapy, the number of combinations currently being pursued
  • Examples of current combinations with TECENTRIQ and other partner molecules
  • Challenges associated with developing combination clinical trial studies – should we change how these trials are designed?
Nov 302:45
Conference pass

Advanced immune characterization using RNA enables biomarker discovery in limiting and diverse samples

Immunotherapy
  • Highlight approaches to characterize the tumor microenvironment and current hurdles
  • Introduction of new technology which reveals immune cell composition present in the tumor, elucidates activated immune-escape pathways, and measures mutational burden to characterize tumor foreignness, all from a single RNA sample
  • Validation data and case study overview
Nov 302:45
Conference pass

Corporate Venture Panel: Unique investment strategies and investing in platform technologies

Funding and Partnerships
  • What are corporate venture firms looking for? What is the best point of entry?
  • What is the nature of the terms and conditions; the unique structure of each CVC firm
  • How closely do we work with our parent companies?
  • Investing in early-stage companies and investment timelines
  • Differences in balance between strategic focus and financial focus.
Nov 302:45
Conference pass

Clinical results of a novel oral Norovirus vaccine

Infectious Diseases
  • Intestinal immunity may be necessary for protection against norovirus infection
  •  Oral immunization induces a robust mucosal memory and effector antibody response
Nov 303:00
Conference pass

Nasal vaccination for respiratory infections

Infectious Diseases
  • Introduction to technology platform; mobilizing the immune system in ways conventional vaccines cannot
  • Key advantages of nasal vaccination
  • NasoVAX seasonal influenza clinical program updates
Nov 303:15
Conference pass

Next generation biomarkers for the era of precision cancer immunotherapy

Immunotherapy
  • “Empiric” and “science-driven” approaches to clinical experimentation are synergistic, and enable iterative learning
  • Novel biomarker tools are needed to enable more accurate interpretation of clinical results from combination I-O clinical trials.
  • Precision immuno-oncology: Biomarkers that describe fundamental parameters of tumor immunobiology are needed to triage patients to the appropriate combination therapies.
  • Implications:
    • Clinical trial design (enrichment, umbrella, basket)
    • Diagnostics: Acceleration of novel biomarkers
    • Regulatory:  Accelerated approval for biomarker-defined populations; complementary diagnostics; tumor-agnostic labeling
Nov 303:15
Conference pass

Progress toward developing a preventive MERS-CoV vaccine

Infectious Diseases
  • Since it was first isolated in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) has caused severe acute lower respiratory disease in more than 2000 people across 27 countries and killed 35% of those it has infected.
  • The high case fatality ratio, broad geographic distribution and absence of a licensed therapy or vaccine has created an imperative for an effective public health countermeasure to MERS
  • Preliminary findings from our first-in-human phase 1 trial of a MERS CoV consensus MERS Spike DNA vaccine are presented and placed in the context of the larger efforts to develop a preventive vaccine for MERS CoV.
Nov 303:30
Conference pass

A Regulatory Perspective --- Clinical Considerations for Novel Immunotherapies

Funding and Partnerships
  • Brief overview of approval processes
  • Review of cell therapies including; adoptive T-cell’s, CAR- T cells, TCRs
  • A closer look at cancer vaccines and neoantigens
Nov 303:45
Conference pass

Increasing the potency of DNA-based immunotherapies using PolyStart peptide expression system

Immunotherapy
  • PolyStart is a unique plasmid DNA construct that expresses four or more peptides for each molecule of mRNA, rather than the dogmatic one DNA = one RNA = one protein
  • How PolyStart can increase the efficiency with which target cells can be identified and elminated
  • Applications in immuno-oncology and potential for use in infectious disease
Nov 303:45
Conference pass

ELISpot and FluoroSpot in vaccine research, development, and evaluation

Infectious Diseases
  • Measure T-cell and B-cell responses at the single cell level
  • Virus cross-reactivity in Influenza
  • Ferret IFN-gamma ELISpot
Nov 304:00
Conference pass

Optimized presentation of antigens using enveloped Virus Like Particles

Infectious Diseases
  • Use of enveloped virus-like particles (eVLPs) for inducing neutralizing antibodies against CMV
  • eVLP expression of multiple antigens for use in immunotherapy
  • Mechanisms responsible for eVLP-based vaccine potency
Nov 304:00
Conference pass

Innovative finance mechanisms for funding vaccine procurement

Funding and Partnerships
  • What financial mechanisms does GAVI use to ensure they can sustain investment in vaccines 
  • Tools used to incentivize certain types of vaccine development
    • E.g. Advanced market commitment to pneumococcal vaccines
  • The vaccine investment strategy process
    • Used to inform GAVI which vaccines they will invest in from 2020
    • GAVI’s view on the landscape of vaccine development
Nov 304:45
Conference pass

Is it time to start considering antibodies as an alternative to vaccines?

Infectious Diseases
  • Synagis® (palivizumab) is the only monoclonal antibody (MAb) currently marketed for prevention of an infectious disease
  • Advances in biologics technology has allowed the development of a highly potent MAb that is being investigated as a vaccine surrogate to protect all infants from RSV disease
  • Are there other diseases, for which vaccine development has been difficult, where MAbs might fill the void?
Nov 304:45
Conference pass

Mechanisms of action of Talimogene Laherparepvec: From Bench to Bedside

Immunotherapy
  • Preclinical data and mechanism of action
  • Updates on clinical data in combination with checkpoint inhibitors
Nov 304:45
Conference pass

The application of machine learning methods to accelerate the development of vaccines and immunotherapies

Funding and Partnerships
  • Brief introduction to key machine learning techniques
  • Examples of where these techniques have already been applied in the development of vaccines.
  • The application of machine learning methods to the initial results of the HVP’s first clinical trial
  • Future outlook and scope of how this technology can help advance the field of vaccines and immunotherapy
Nov 305:00
Conference pass

Delivering multiple immunotherapies in a single construct; what makes WO-12 unique amongst oncolytic virotherapies?

Immunotherapy
  • WO-12 is an immuno-oncolytic virus engineered to replicate in cancer cells while delivering therapeutic transgenes that train the immune system to target the tumor
  • How does WO-12's interaction with TLR signalling pathways result in increased beneficial T-Cell responses while reducing the antibody response?
  • The importance of modifying the tumour micro-environment in eliciting good immunotherapeutic responses
  • Challenges to overcome in achieving systemic delivery
  • Outlook for beginning of human clinical trials in 2018
Nov 305:15
Conference pass

The generation and modulation of immunogenic cell death using oncolytic viruses

Immunotherapy
  • What is immunogenic cell death? Mechanism and modulation by oncolytic viruses
  • Signalling pathways that regulate the tumor immunosuppressive milieu and their alteration
  • Cancer stem cells immunology and inhibition of tumor immune escape
  • Modulation of immunogenic cell death by combining oncolytic viruses with other therapies
Nov 305:15
Conference pass

Blue Marble Health: An Innovative Plan to Fight Diseases of the Poor Amid Wealth

Funding and Partnerships
  • Today most of the poverty-related neglected diseases are found in G20 nations
  • The poor living among the wealthy account for this disease burden
  • This provides a key policy framework for new innovations to address the world's poverty-related neglected diseases
  • Examples in the context of Zika, and other emerging infections
Nov 305:15
Conference pass

Using 3D Cryo-electron microscopy technology to determine the structures of vaccine nanoparticles to enable better vaccine design

Infectious Diseases
  • Using state of the art structural biology techniques to design nanoparticles that display conserved epitopes; influenza case study
  • The importance of conformational state in B-cell activation
  • Potential for use in other infectious diseases and immunotherapy
  • The future of immunogen design to elicit the required antibodies and the characterisation of therapeutic antibodies to boost immune response

Create your personal agenda –check the favourite icon

Dec 108:30
Conference pass
Dec 108:40
Conference pass

Precision oncology needs data sharing: Integrating genomic and clinical data to advance patient care and understanding patient outcomes

Keynotes
  • Does decoding the genes of patients’ cancer help to accelerate the pace of discovery?
  • Is more sequencing, across large populations worthwhile?
  • How to combine all these data into one searchable pool?
  • How will this translate to better and more personalized vaccines or treatments for patients?
  • The paradigm of bringing multiple cancer centers together, connecting academics with industry and how to data share
  • The type of data sharing necessary to learn from the experience of patients that go through cancer immunotherapy
Dec 109:30
Conference pass

How to effectively manipulate the microbiome to improve efficacy of vaccines and immunotherapy

Keynotes
  • Understanding the microbiome and its interaction with the immune system
  • What evidence is there that one can change the other?
  • Potential opportunities and current challenges in harnessing this knowledge into better treatments
Dec 110:00
Conference pass

Discussion: Driving innovation – Helping biotech’s to succeed from inception to expansion

Keynotes
  • What models can be used to support innovation?
  • What criteria do we look for in choosing biotech’s to work with?
  • How to be successful; programs and strategies to grow your company – how does this apply to vaccines and immunotherapy?
Dec 111:41
Conference pass

Common logistics challenges that can delay clinical trials

Keynotes
Dec 111:41
Conference pass
Dec 111:41
Conference pass

In vivo evaluation of biomarkers and immune correlates of vaccine-induced protection

Keynotes
Dec 111:41
Conference pass

Microbiome biomarkers for cancer immunotherapy: promise and challenges

Keynotes
Dec 111:41
Conference pass

Quality assurance and quality compliance in the development of personalised cancer vaccines

Keynotes
Dec 111:41
Conference pass

Overcoming clinical challenges that occur with combining different immuno-oncology approaches

Keynotes
Dec 111:41
Conference pass
Dec 12:10
Conference pass
Dec 12:15
Conference pass

Developing vaccines for viral infections: Addressing HIV and Zika vaccine development

Infectious Diseases
  • Results of Ph1b study for HIV vaccine
  • Moving into Ph11a proof of concept studies
  • Results of Zika pre-clinical studies
  • Preparing for Zika first in human trials
  • Has interest in Zika diminished? Impact on vaccine development
Dec 12:15
Conference pass

Development of novel, personalized neoantigen immunotherapies

Immunotherapy
  • Using real time next-generation sequencing and bioinformatics approaches to identify and catalogue neoepitopes for each patient
  • How algorithms have increased the accuracy of identifying neoepitopes from 1% - 40%
  • Manufacture and delivery of personalized cancer vaccines either alone or in combination with other therapeutics
Dec 12:45
Conference pass

Development of a correlate of protection for a live oral cholera vaccine

Infectious Diseases
  • Review of the immune response to cholera
  • Protective efficacy in a human challenge model
  • Establishment of a correlate for use in pre-licensure studies
  • Extension of this approach for post-approval studies
Dec 12:45
Conference pass

Optimizing the therapeutic benefit of PD-1 blockade and broadening the potential of immunotherapy

Immunotherapy
  • The past, present and future of anti-PD-1 therapies
  • Where are we currently with Keytruda monotherapy and biomarkers
  • Updates on our combination strategy and trials with Keytruda and other novel agents
Dec 13:15
Conference pass

Progress of chimeric antigen receptor (CAR) T-cells as an immuno-oncology treatment

Immunotherapy
  • Preliminary clinical outcomes of FIM clinical trial of CAR-GPC3 T cells in patients with advanced hepatocellular carcinoma
  • Bottlenecks in tech transfer for CAR-GPC3 T cells cross board manufacturing
  • Regulatory considerations when planning CAR-T clinical trials in China vs in US
Dec 13:15
Conference pass

The use of next generation self-amplifying RNA platform systems for vaccine development

Infectious Diseases
  • Why self-amplifying RNA systems?
  • Engineering beneficial attributes into RNA systems
  • In vitro analysis of engineered attributes
  • In vivo analysis of engineered attributes
  • Impact of engineered attributes on immunogenicity
Dec 14:00
Conference pass

Electroporation mediated DNA immunization: Clinical progress and technology development

Infectious Diseases
  • Review of clinical experience with electroporation based intradermal and intramuscular DNA vaccination
  • Development of electroporation device technology to support the development & deployment of novel DNA vaccine candidates
  • Adaptation of electroporation for delivery of DNA encoding monoclonal antibodies
Dec 14:00
Conference pass

Combining innate cellular therapy and adaptive immune therapy approaches for treatment of recurrent cancer

Immunotherapy
  • Rationale for combination of adenoviral vaccine with “superkine” IL-15 agonist
  • Partnering with NK cell therapy – mechanisms of action
  • Study design and initial safety
  • Early response data
Dec 14:15
Conference pass

Development of a next generation rPA based anthrax vaccine

Infectious Diseases
Dec 14:30
Conference pass

Immune profiling of T cell responses correlating with pertussis vaccine efficacy

Infectious Diseases
  • Introduction of a whole cell pertussis vaccine in the 1950s led to dramatic reduction in morbidity
  • Whole pertussis inactivated vaccine was associated with significant side effects, replaced in 1997 with acellular version
  • Resurgence of pertussis in teenagers – age of people affected correlates with time when vaccine switched from whole cell vaccine to acellular vaccine occurred
  • Discussion of changes that have been identified in in immune profile between old vaccine and new
Dec 14:30
Conference pass

Beyond PD1s – Using a tumours composition to activate an immune response through STING pathway

Immunotherapy
  • Mode of action
  • Planned and ongoing clinical studies
  • Combination with vaccines
  • The importance of STING activation in priming patient’s tumours to respond to checkpoint inhibition
last published: 23/Nov/17 12:35 GMT